Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
2.5
-91.83%
40%
—
-91.83%
20%
—
5 Years
Score2.5
Net Growth-91.83%
Net Trend40%
Net Income Consistency—
Rev Growth-91.83%
Rev Trend20%
Revenue Consistency—
Innate Pharma fundamental performance
Across Innate Pharma's full reported history, from 2019 to 2025, revenue declined from € 68M to € 2M and net income went from -€ 20M to -€ 47M. Revenue increased in 29% of the years measured; net income in 43%.
Innate Pharma currently holds a 5-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 2.47 | — |
1 Year2025-08-12 | $ 2.07 | 19.32% |
5 Years2021-08-12 | $ 3.28 | -24.70% |
All Time2019-10-17 | $ 6.05 | -59.17% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2019-10-17 |
|---|---|---|---|---|
| Price | $ 2.47 | $ 2.07 | $ 3.28 | $ 6.05 |
| Return | — | 19.32% | -24.70% | -59.17% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | € 990K | -€ 101M | € 34M |
| 2025 | € 2M | -€ 47M | € 34M |
| 2024 | € 12M | -€ 49M | € 80M |
| 2023 | € 51M | -€ 7M | € 92M |
| 2022 | € 57M | -€ 58M | € 101M |
| 2021 | € 12M | -€ 52M | € 119M |
| 2020 | € 69M | -€ 63M | € 151M |
| IPO2019 | € 68M | -€ 20M | € 218M |
Explore beyond IPHA
You're looking at Innate Pharma. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
